I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Wach, Malgorzata
65
results:
Search for persons
X
Format
Online (65)
Mediatypes
Articles (Online) (21)
Bookchapter (Online) (2)
OpenAccess-fulltext (42)
Languages
english (55)
german (1)
more...
polish (4)
less...
Sorted by: Relevance
Sorted by: Year
?
1
The Outcomes of Ponatinib Therapy in Patients With Chronic ..:
Sacha, Tomasz
;
Szczepanek, Elżbieta
;
Dumnicka, Paulina
...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) 6 - p. 405-415 , 2022
Link:
https://doi.org/10.1016/..
?
2
Acalabrutinib Versus Investigator's Choice in Relapsed/Refr..:
Ghia, Paolo
;
Pluta, Andrzej
;
Wach, Małgorzata
...
HemaSphere. 6 (2022) 12 - p. e801 , 2022
Link:
https://doi.org/10.1097/..
?
3
CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (Id..:
Ghia, Paolo
;
Pluta, Andrzej
;
Wach, Malgorzata
...
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) - p. S220-S221 , 2020
Link:
https://doi.org/10.1016/..
?
4
Idelalisib addition has neutral to beneficial effects on qu..:
Montillo, Marco
;
Illés, Árpád
;
Robak, Tadeusz
...
Health and Quality of Life Outcomes. 17 (2019) 1 - p. , 2019
Link:
https://doi.org/10.1186/..
?
5
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamu..:
Ghia, Paolo
;
Pluta, Andrzej
;
Wach, Malgorzata
...
Clinical Lymphoma Myeloma and Leukemia. 19 (2019) - p. S280-S281 , 2019
Link:
https://doi.org/10.1016/..
?
6
Advances in hematology – research that revolutionized patie..:
Wach, Małgorzata
;
Podhorecka, Monika
;
Cioch, Maria
...
Polish Journal of Public Health. 125 (2015) 1 - p. 32-35 , 2015
Link:
https://doi.org/10.1515/..
?
7
Different prognosis of acute myeloid leukemia harboring mon..:
Wawrzyniak, Ewa
;
Wierzbowska, Agnieszka
;
Kotkowska, Aleksandra
...
Leukemia Research. 37 (2013) 3 - p. 293-299 , 2013
Link:
https://doi.org/10.1016/..
?
8
Neutropenic enterocolitis: a serious complication during th..:
Wach, Malgorzata
;
Dmoszynska, Anna
;
Wasik-Szczepanek, Ewa
...
Annals of Hematology. 83 (2003) 8 - p. , 2003
Link:
https://doi.org/10.1007/..
?
9
Intravascular B-cell lymphoma in a 38-year-old woman: a cas..:
Wach, Małgorzata
;
Dmoszyńska, Anna
;
Skomra, Danuta
..
Annals of Hematology. 80 (2001) 4 - p. 224-227 , 2001
Link:
https://doi.org/10.1007/..
?
10
Idelalisib addition has neutral to beneficial effects on qu..:
Montillo, Marco
;
Illés, Árpad
;
Robak, Tadeusz
...
10.1186/s12955-019-1232-8. , 2023
Link:
https://hdl.handle.net/2..
?
11
Acalabrutinib Versus Investigator's Choice in Relapsed/Refr..:
Ghia, Paolo
;
Pluta, Andrzej
;
Wach, Malgorzata
...
HemaSphere. -6 : 12 (2022), p. 1-10. -Hemasphere. - 2572-9241. , 2022
Link:
https://hdl.handle.net/2..
?
12
Acalabrutinib Versus Investigator's Choice in Relapsed/Refr..:
Ghia, Paolo
;
Pluta, Andrzej
;
Wach, Małgorzata
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666115/. , 2022
Link:
http://www.ncbi.nlm.nih...
?
13
Idelalisib addition has neutral to beneficial effects on qu..:
Montillo, Marco
;
Illés, Árpad
;
Robak, Tadeusz
...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12955-019-1232-8. , 2019
Link:
https://hal.univ-lille.f..
?
14
Idelalisib addition has neutral to beneficial effects on qu..:
Montillo, Marco
;
Illés, Árpád
;
Robak, Tadeusz
...
Health and Quality of Life Outcomes. -17 : 1 (2019) p. 1-11. -Health Qual. Life Outcomes. - 1477-7525. - 1477-7525. , 2019
Link:
http://hdl.handle.net/24..
?
15
Idelalisib addition has neutral to beneficial effects on qu..:
Montillo, Marco
;
Illés, Árpad
;
Robak, Tadeusz
...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12955-019-1232-8. , 2019
Link:
https://hal.univ-lille.f..
1-15